Description: Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Home Page: www.inva.com
INVA Technical Analysis
1350 Old Bayshore Highway
Burlingame,
CA
94010
United States
Phone:
650 238 9600
Officers
| Name | Title |
|---|---|
| Mr. Pavel Raifeld C.F.A. | Chief Exec. Officer |
| Ms. Marianne Zhen CPA | Chief Accounting Officer & Sec. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 3.9636 |
| Price-to-Book MRQ: | 1.4438 |
| Price-to-Sales TTM: | 2.4232 |
| IPO Date: | 2004-10-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |